StockNews.AI
PHVS
StockNews.AI
53 days

Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit

1. Pharvaris presents at US Hereditary Angioedema Association Summit in July 2025. 2. Key presentations on oral Deucrictibant's efficacy for hereditary angioedema planned. 3. Positive Phase 2 results set up pivotal Phase 3 studies for HAE treatment. 4. Focus on long-term safety, efficacy, and quality of life improvements with Deucrictibant. 5. Posters available on Pharvaris' investor website during presentations starting July 11.

5m saved
Insight
Article

FAQ

Why Bullish?

The acceptance of abstracts suggests strong interest in Pharvaris' research, potentially boosting investor confidence. Previous positive trial results have historically correlated with stock price appreciation for biopharmaceuticals.

How important is it?

The article focuses on significant clinical developments, essential for informing investors and stakeholders about PHVS's future path.

Why Long Term?

The upcoming presentations will likely enhance Phvs visibility and market positioning. Positive outcomes from Phase 3 trials could lead to increased sales projections and long-term investor interest.

Related Companies

AAOIHZO
June 27, 2025 06:50 ET  | Source: Pharvaris N.V. ZUG, Switzerland, June 27, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of abstracts for presentation at the US Hereditary Angioedema Association's 2025 National Summit to be held from July 10-13, 2025, in Baltimore, Maryland. Details of the presentations are as follows: Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension Study Presenter: Michael E. Manning, M.D.Format: Poster Presentation, #22Date, time: Friday, July 11, 12:30-13:30 ETTitle: Long-Term Prophylactic Treatment with Oral Deucrictibant Improves Disease Control and Health-Related Quality of Life in Participants with Hereditary Angioedema: CHAPTER-1 Open-Label Extension StudyPresenter: Michael E. Manning, M.D.Format: Poster Presentation, #20Date, time: Friday, July 11, 12:30-13:30 ETTitle: CHAPTER-3 Phase 3 Trial Design: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema AttacksPresenter: H. Henry Li, M.D., Ph.D.Format: Poster Presentation, #5Date, time: Friday, July 11, 12:30-13:30 ETTitle: Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension StudyPresenter: Marc A. Riedl, M.D., M.S.Format: Poster Presentation, #23Date, time: Friday, July 11, 12:30-13:30 ETTitle: Durability of response to a single dose of oral deucrictibant for on-demand treatment of hereditary angioedema attacksPresenter: Joshua S. Jacobs, M.D.Format: Poster Presentation, #9Date, time: Friday, July 11, 12:30-13:30 ETTitle: Deucrictibant vs. Standard of Care in Hereditary Angioedema: A Propensity Score-Matched AnalysisPresenter: Mark D. Scarupa, M.D. Format: Poster Presentation, #7Date, time: Friday, July 11, 12:30-13:30 ET The posters will be made available on the Investors section of the Pharvaris website at the beginning of the respective presentations at: https://ir.pharvaris.com/news-events/events-presentations. About PharvarisPharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to potentially address all types of bradykinin-mediated angioedema. Pharvaris intends to provide injectable-like efficacy™ and placebo-like tolerability with the convenience of oral therapies to prevent and treat bradykinin-mediated angioedema attacks. With positive data in both Phase 2 prophylaxis and on-demand studies in HAE, Pharvaris is currently evaluating the efficacy and safety of deucrictibant in a pivotal Phase 3 study for the prevention of HAE attacks (CHAPTER-3) and a pivotal Phase 3 study for the on-demand treatment of HAE attacks (RAPIDe-3). For more information, visit https://pharvaris.com/. Contact Maggie Beller Executive Director, Head of Corporate and Investor Communications maggie.beller@pharvaris.com

Related News